Allergan And Editas Medicine Enter Into R&D Alliance – Bio-IT World
|
Allergan And Editas Medicine Enter Into R&D Alliance
Bio-IT World The agreement covers early stage, first-in-class ocular programs targeting serious diseases based on Editas Medicine's CRISPR genome editing platform, including CRISPR/Cas9 and CRISPR/Cpf1. Editas Medicine's lead program is being developed for the … Allergan (AGN) and Editas Tie Up to Treat Eye Diseases Allergan makes a deal with Editas to License CRISPR Programs for Eye Disease Allergan and Editas Medicine Enter into R&D Alliance for Eye Diseases |
